New treatment paradigms for resectable nonsmall cell lung cancer (NSCLC), with an emphasis on personalised care and a multidisciplinary approach, have significantly improved patient outcomes. The incorporation of immune checkpoint inhibitors into neoadjuvant, perioperative and adjuvant treatment algorithms is reshaping the standard of care for resectable NSCLC. Adjuvant targeted therapy trials have also paved the way for a much-needed personalised approach for patients with actionable genomic alterations. Innovative surgical techniques and judicious use of postoperative radiotherapy may mitigate the toxicity associated with a multimodality approach. Amid the many new treatment options, questions remain about the best approach to consider for each patient. Measurement of minimal residual disease and achievement of pathological complete response are emerging biomarkers of interest to help further refine treatment selection. This review summarises the current management of resectable NSCLC, focusing on ongoing and recent advances in surgical approaches, the role of postoperative radiotherapy and the rapidly changing field of systemic therapies.

可切除非小细胞肺癌（NSCLC）的新治疗模式强调个性化护理和多学科方法，显着改善了患者的治疗效果。将免疫检查点抑制剂纳入新辅助、围手术期和辅助治疗流程中正在重塑可切除非小细胞肺癌的护理标准。辅助靶向治疗试验也为具有可操作基因组改变的患者提供急需的个性化方法铺平了道路。创新的手术技术和明智地使用术后放疗可能会减轻与多模式治疗相关的毒性。在许多新的治疗方案中，对于每个患者应考虑的最佳方法仍然存在疑问。微小残留病的测量和病理完全缓解的实现是新兴的生物标志物，有助于进一步完善治疗选择。本综述总结了可切除非小细胞肺癌的当前治疗，重点关注手术方法的持续和最新进展、术后放疗的作用以及快速变化的全身治疗领域。